Inhibrx Biosciences, Inc. · NASDAQ:INBX

Inhibrx Biosciences — Technical Presentation (October 2026)

16 slides from Inhibrx Biosciences's technical presentation, Oct 25, 2026

  1. Slide 1: HexAgon-HN: Phase 2 Primary Analysis of Ordastobart plus Pembrolizumab in HNSCC

    HEXAGON-HN: A PHASE 2/3 STUDY OF THE HEXAVALENT OX40 AGONIST ORDASTOBART (INBRX-106) IN COMBINATION WITH PEMBROLIZUMAB AS FIRST-LINE TREATMENT OF PD-L1–HIGH RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA—PHASE 2 PRIMARY ANALYSIS Jong Chul Park,1 Lisa Licitra,2 Eun Joo Kang,3 Dan P. Zandb

  2. Slide 2: Declaration of Interests

    DECLARATION OF INTERESTS JC Park reports research funding to his institution from A2 Biotherapeutics, ALX Oncology, Ankyra Therapeutics, AVEO, BioNTech, DualityBio, GSK, Hanmi, Inhibrx, and Pyxis Oncology; and consult honoraria from Coherus, Hanmi, and ABL Bio. Presenter: Jong Chul Park, MD Content

  3. Slide 3: Background: INBRX-106, engineered hexavalent OX40 agonist

    BACKGROUND INBRX-106: engineered hexavalent OX40 agonist • OX40 is a TNF-receptor family costimulatory receptor on 6x single-domain antibodies activated T cells that enhances anti-tumor T-cell responses simultaneously engage multiple OX40 molecules to drive hyperclustering • INBRX-106 (ordastobart)

  4. Slide 4: HexAgon-HN Study Design

    HEXAGON-HN STUDY DESIGN Phase 2/3 randomized study of INBRX-106 + pembro vs pembro as 1L tx for patients with R/M HNSCC, PD-L1 CPS ≥201,2 • CPS ≥20 selection: strongest established activity of pembro monotherapy provides clearest benchmark to test combination, and subpopulation was initially hypothe

  5. Slide 5: Baseline Characteristics

    BASELINE CHARACTERISTICS INBRX-106 + pembro Pembro INBRX-106 + pembro Pembro Demographics Disease characteristics n=33 n=35 n=33 n=35 Age, median (range), y 62.0 (35-80) 66.0 (44-89) Disease status,a n (%) Sex, n (%) Locoregional recurrent 15 (45.5) 14 (40.0) Male / female 30 (90.9) / 3 (9.1) 28 (80

  6. Slide 6: Patient Disposition

    PATIENT DISPOSITION INBRX-106 + pembro Pembro Total randomized Patient disposition n=33 n=35 N=68 Ongoing treatment, n (%) 11 (33.3) 8 (22.9) 19 (27.9) Discontinued treatment, n (%) 22 (66.7) 27 (77.1) 49 (72.1) Post-treatment follow-up 12 (36.4) 17 (48.6) 29 (42.6) tumor assessment / OS, n (%) Disc

  7. Slide 7: Primary Efficacy Endpoint: cORR

    PRIMARY EFFICACY ENDPOINT: cORR INBRX-106 + pembro (n=29) Pembro (n=34) 80 cORR, 48.3% (14/29) 80 cORR, 26.5% (9/34) TL SOD best change from BL, % (95% CI, 12.9-44.4) TL SOD best change from BL, % 60 (95% CI, 29.4-67.5) 60 40 40 20 20 0 0 -20 -20 -40 -40 -60 -60 -80 -80 -100 CR PR SD PD -100 PR SD P

  8. Slide 8: Secondary Efficacy Endpoints: PFS6mo and CBR

    SECONDARY EFFICACY ENDPOINTS: PFS6mo and CBR INBRX-106 + pembro (n=29) Pembro (n=34) ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ PFS6mo, 72.4% ★ PFS6mo, 42.8% ★ (95% CI, 52.3-85.1) ★ (95% CI, 25.2-59.2) ★ ★ ★ ★ CBR, 72.4% ★ CBR, 58.8% ★ ★ CR PR SD PD PR SD PD ★ Ongoing, progression free ★ Ongoing, progression free 0

  9. Slide 9: Subgroup Analysis by Stratification Factors

    SUBGROUP ANALYSIS BY STRATIFICATION FACTORS Disease status HPV status ECOG PS INBRX-106 + INBRX-106 + INBRX-106 + Pembro Pembro Pembro pembro pembro pembro Locoreg rec, n 14 14 HPV-positive, n 10 9 ECOG PS 0, n 15 16 cORR, % 42.9 14.3 cORR, % 80.0 33.3 cORR, % 46.7 31.3 ΔORR, % 28.6 ΔORR, % 46.7 ΔOR

  10. Slide 10: Efficacy in HPV-Positive Disease: ORR

    EFFICACY IN HPV-POSITIVE DISEASE: ORR INBRX-106 + pembro (n=10) Pembro (n=9) 40 cORR, 80.0% 40 cORR, 33.3% (95% CI, 44.4-97.5) (95% CI, 7.5-70.1) 20 20 TL SOD best change from BL, % TL SOD best change from BL, % 0 0 -20 -20 -40 -40 -60 -60 -80 -80 -100 CR PR SD PD -100 PR SD PD • Greater treatment e

  11. Slide 11: Efficacy in HPV-Positive Disease: PFS6mo

    EFFICACY IN HPV-POSITIVE DISEASE: PFS6mo INBRX-106 + pembro (n=10) Pembro (n=9) ★ ★ ★ ★ ★ ★ ★ PFS6mo, 90% PFS6mo, 33% ★ ★ ★ ★ CR PR SD PD PR SD PD ★ Ongoing, progression free ★ Ongoing, progression free 0 6 12 18 0 6 12 18 Time on study, mo Time on study, mo • Greater and durable treatment effect in

  12. Slide 12: Pharmacodynamics

    PHARMACODYNAMICS Proliferation Activation Max fold change from baseline, % of proliferating memory cells Max fold change from baseline, % of activated memory cells • Translational findings in peripheral blood in CD4+ T cells HexAgon-HN support validation of INBRX-106 as a potent T-cell co-activator

  13. Slide 13: Safety

    SAFETY INBRX-106 + Most frequent TRAEs (≥10% of patients) pembro Pembro Rash maculopapular 32.3 9.7 0.0 Patients with ≥1 TEAE, n(%) n=31 n=34 Rash 32.3 3.2 11.8 TEAE 31 (100) 29 (85.3) Fatigue 29.0 3.2 2.9 11.8 Diarrhea 29.0 9.7 5.9 Tx-related 27 (87.1) 20 (58.8) ALT increased 6.5 2.9 8.8 25.8 SAE 1

  14. Slide 14: Conclusions

    CONCLUSIONS • Addition of INBRX-106 to pembro as 1L treatment for patients with R/M HNSCC with PD-L1 CPS ≥20 improved cORR (48.3% vs 26.5%), supported by PFS6mo (72.4% vs 42.8%) • In the prespecified subgroup of patients with HPV-positive disease, a more pronounced benefit (cORR, 80.0% vs 33.3%; PFS

  15. Slide 15: Acknowledgments

    ACKNOWLEDGMENTS • We thank our patients and participating clinical sites and teams Copies of this presentation obtained through QR, AR and/or text key codes are for personal use only and may not be reproduced without written permission of the authors Presenter: Jong Chul Park, MD Content of this pre

  16. Slide 16: Thank you!

    Copies of this presentation obtained through QR, AR and/or text key codes are for personal use only and may not be reproduced without written Thank you! permission of the authors European Society for Medical Oncology (ESMO) Via Ginevra 4, CH-6900 Lugano T. +41 (0)91 973 19 00 esmo@esmo.org esmo.org

Inhibrx Biosciences — Technical Presentation (October 2026) on 6ix